The expression and clinical significance of lymphocyte subsets and immunoglobulins in children with autism spectrum disorder

GUO Xuesong; MIAO Wenjing; FENG Xiujuan; WANG Dahai; WANG Chunyan; CHEN Liye

doi:10.7619/jcmp.20233562

Journal of Clinical Medicine in Practice > 2024 > 28(4): 111-114, 124. > DOI: 10.7619/jcmp.20233562

GUO Xuesong, MIAO Wenjing, FENG Xiujuan, WANG Dahai, WANG Chunyan, CHEN Liye. The expression and clinical significance of lymphocyte subsets and immunoglobulins in children with autism spectrum disorder[J]. Journal of Clinical Medicine in Practice, 2024, 28(4): 111-114, 124. DOI: 10.7619/jcmp.20233562

Citation:

PDF (872 KB)

The expression and clinical significance of lymphocyte subsets and immunoglobulins in children with autism spectrum disorder

Department of Rehabilitation of Jiangnan Branch, Heilongjiang Hospital of Beijing Children's Hospital Affiliated to Capital Medical University, the Sixth Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, 150010

More Information

Received Date: November 07, 2023
Revised Date: January 09, 2024
Available Online: March 05, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the expression levels and clinical significance of absolute counts of lymphocyte subsets and immunoglobulins (Ig) in peripheral blood of children with autism spectrum disorder (ASD).
Methods
Seventy-five children with ASD were selected as study group, and another 75 healthy children who underwent physical examination were selected as control group. Flow cytometry was used to detect the absolute counts of lymphocyte subsets (CD3⁺, CD4⁺, CD8⁺, CD19⁺, CD56⁺CD16⁺) and IgA, IgG, IgM levels in peripheral blood of both groups of children. Pearson correlation analysis was used to explore the correlation between each detection index and the total score of the Childhood Autism Rating Scale (CARS).
Results
The number of absolute counts of CD3⁺ and CD4⁺ in the study group were (62.49±8.71) and (34.87±7.86) in one μL, respectively, which were separately lower than (67.73±5.11) and (39.56±4.60)]in one μL in the control group (P < 0.05). There were no significant differences in the absolute counts of CD8⁺, CD19⁺, CD56⁺CD16⁺ between the two groups (P>0.05). The levels of IgA, IgG, IgM in the study group were (0.79±0.33), (8.39±2.03), (0.95±0.27), respectively, which were lower than (0.94±0.29), (9.28±1.37), (1.16±0.39) in the control group (P < 0.05). Pearson correlation analysis showed that IgA level was significantly negatively correlated with CARS total score (r= -0.317, P=0.034), while the absolute counts of CD3⁺, CD4⁺, CD8⁺, CD19⁺, CD56⁺CD16⁺ and IgG, IgM levels had no correlation with CARS total score (P>0.05).
Conclusion
Abnormal expression levels of lymphocyte subsets and Ig-mediated immune dysfunction are closely related to the occurrence of ASD in children. CD3⁺, CD4⁺, IgA, IgG, and IgM can be used as potential biological indicators for screening the immunological etiology of ASD in children, and IgA can be used as an indicator for evaluating the efficacy of ASD children with immunological etiology.
- lymphocyte subsets,
- immunoglobulins,
- immunity,
- autism spectrum disorder,
- children

FullText(HTML)

References (28)

References

[1]	占红, 白淑霞, 王金堂. 屏幕暴露与儿童孤独症谱系障碍的相关性研究[J]. 实用临床医药杂志, 2021, 25(22): 46-49, 54. doi: 10.7619/jcmp.20212094
[2]	ROBINSON-AGRAMONTE M L A, NORIS GARCÍA E, FRAGA GUERRA J, et al. Immune dysregulation in autism spectrum disorder: what do we know about it[J]. Int J Mol Sci, 2022, 23(6): 3033. doi: 10.3390/ijms23063033
[3]	PANGRAZZI L, BALASCO L, BOZZI Y. Oxidative stress and immune system dysfunction in autism spectrum disorders[J]. Int J Mol Sci, 2020, 21(9): 3293. doi: 10.3390/ijms21093293
[4]	BAXTER A J, BRUGHA T S, ERSKINE H E, et al. The epidemiology and global burden of autism spectrum disorders[J]. Psychol Med, 2015, 45(3): 601-613. doi: 10.1017/S003329171400172X
[5]	MAENNER M J, WARREN Z, WILLIAMS A R, et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 sites, United States, 2020[J]. MMWR Surveill Summ, 2023, 72: 1-14.
[6]	ZHOU H, XU X, YAN W L, et al. Prevalence of autism spectrum disorder in China: a nationwide multi-center population-based study among children aged 6 to 12 years[J]. Neurosci Bull, 2020, 36(9): 961-971. doi: 10.1007/s12264-020-00530-6
[7]	谢姝, 刘瑜, 李德欣, 等. 内源性大麻素系统对孤独症谱系障碍异常神经炎症反应调控作用的研究进展[J]. 中国儿童保健杂志, 2022, 30(4): 392-395. https://www.cnki.com.cn/Article/CJFDTOTAL-ERTO202204010.htm
[8]	卢彦宇, 韩颖. 孤独症谱系障碍的免疫相关机制与治疗研究进展[J]. 中华儿科杂志, 2022, 60(5): 482-486. https://www.cnki.com.cn/Article/CJFDTOTAL-YXJZ202304005.htm
[9]	MOLLOY C A, MORROW A L, MEINZEN-DERR J, et al. Elevated cytokine levels in children with autism spectrum disorder[J]. J Neuroimmunol, 2006, 172(1/2): 198-205.
[10]	GUPTA S. Immunological treatments for autism[J]. J Autism Dev Disord, 2000, 30(5): 475-479. doi: 10.1023/A:1005568027292
[11]	ASHWOOD P, KRAKOWIAK P, HERTZ-PICCIOTTO I, et al. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome[J]. Brain Behav Immun, 2011, 25(1): 40-45. doi: 10.1016/j.bbi.2010.08.003
[12]	GŁADYSZ D, KRZYWDZINSKA A, HOZYASZ K K. Immune abnormalities in autism spectrum disorder-could they hold promise for causative treatment[J]. Mol Neurobiol, 2018, 55(8): 6387-6435. doi: 10.1007/s12035-017-0822-x
[13]	WARREN R P, ODELL J D, WARREN W L, et al. Brief report: immunoglobulin A deficiency in a subset of autistic subjects[J]. J Autism Dev Disord, 1997, 27(2): 187-192. doi: 10.1023/A:1025895925178
[14]	HEUER L, ASHWOOD P, SCHAUER J, et al. Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms[J]. Autism Res, 2008, 1(5): 275-283. doi: 10.1002/aur.42
[15]	HEUER L S, ROSE M, ASHWOOD P, et al. Decreased levels of total immunoglobulin in children with autism are not a result of B cell dysfunction[J]. J Neuroimmunol, 2012, 251(1/2): 94-102.
[16]	ROBINSON-AGRAMONTE M L A, NORIS GARCÍA E, FRAGA GUERRA J, et al. Immune dysregulation in autism spectrum disorder: what do we know about it[J]. Int J Mol Sci, 2022, 23(6): 3033. doi: 10.3390/ijms23063033
[17]	EBRAHIMI MEIMAND S, ROSTAM-ABADI Y, REZAEI N. Autism spectrum disorders and natural killer cells: a review on pathogenesis and treatment[J]. Expert Rev Clin Immunol, 2021, 17(1): 27-35. doi: 10.1080/1744666X.2020.1850273
[18]	WASILEWSKA J, KACZMARSKI M, STASIAK-BARMUTA A, et al. Low serum IgA and increased expression of CD23 on B lymphocytes in peripheral blood in children with regressive autism aged 3-6 years old[J]. Arch Med Sci, 2012, 8(2): 324-331.
[19]	PETERSON M, PRIGGE M B D, BIGLER E D, et al. Evidence for normal extra-axial cerebrospinal fluid volume in autistic males from middle childhood to adulthood[J]. Neuroimage, 2021, 240: 118387. doi: 10.1016/j.neuroimage.2021.118387
[20]	RUNGE K, FIEBICH B L, KUZIOR H, et al. Altered cytokine levels in the cerebrospinal fluid of adult patients with autism spectrum disorder[J]. J Psychiatr Res, 2023, 158: 134-142. doi: 10.1016/j.jpsychires.2022.12.032
[21]	PETROZZIELLO T, AMARAL A C, DUJARDIN S, et al. Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid[J]. Brain Pathol, 2022, 32(2): e13035. doi: 10.1111/bpa.13035
[22]	AHMAD S F, ANSARI M A, NADEEM A, et al. Dysregulation of T cell immunoglobulin and mucin domain 3 (TIM-3) signaling in peripheral immune cells is associated with immune dysfunction in autistic children[J]. Mol Immunol, 2019, 106: 77-86.
[23]	ROSSIGNOL D A, FRYE R E. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures[J]. Mol Psychiatry, 2012, 17(4): 389-401.
[24]	ROSSIGNOL D A, FRYE R E. A systematic review and meta-analysis of immunoglobulin G abnormalities and the therapeutic use of intravenous immunoglobulins (IVIG) in autism spectrum disorder[J]. J Pers Med, 2021, 11(6): 488.
[25]	MELAMED I R, HEFFRON M, TESTORI A, et al. A pilot study of high-dose intravenous immunoglobulin 5% for autism: impact on autism spectrum and markers of neuroinflammation[J]. Autism Res, 2018, 11(3): 421-433.
[26]	SHARMA A, GOKULCHANDRAN N, SANE H, et al. Autologous bone marrow mononuclear cell therapy for autism: an open label proof of concept study[J]. Stem Cells Int, 2013, 2013: 623875.
[27]	LV Y T, ZHANG Y, LIU M, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism[J]. J Transl Med, 2013, 11: 196.
[28]	DAWSON G, SUN J M, DAVLANTIS K S, et al. Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase Ⅰ open-label trial[J]. Stem Cells Transl Med, 2017, 6(5): 1332-1339.

Cited By

Get Citation

PDF

XML

Article views (110) PDF downloads (3)

Turn off MathJax

Article Contents

Abstract

References

The expression and clinical significance of lymphocyte subsets and immunoglobulins in children with autism spectrum disorder

Abstract

References

Catalog

Export File

Citation

Format

Content